跳至主要内容
临床试验/NCT02618265
NCT02618265Unknown不适用

Mobile Terminal Based Management and Platelet Reactivity Modified Drug Regulation of Stroke Secondary Prevention

Peking University Third Hospital1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2016年1月最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
400
试验地点
1
主要终点
change of the stroke recurrence rate

研究概览

简要总结

The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform. Whole blood-impedance based platelet aggregation(WBA) method and VerifyNow detected by aspirin or clopidogrel responsiveness will provide individualized anti-platelet drug selection. Endpoint event is defined as stroke death or relapse. Primary measure outcomes are change of the stroke recurrence rate and mortality after secondary prevention.

详细描述

With high incidence, mortality, morbidity and recurrence rate,stroke has significant impact on national development strategies planning. Improving secondary prevention will strongly promote stroke management in the rapid developing phase of Chinese economy and expansion of health situation. At present lack of high-quality medical resources, low medical permeability cannot remedy extensive prevention failure of stroke. Mobile healthcare is easier to conduct and still in the early stage of explosive growth. This research group has established an open management platform of stroke prevention. And collaborate with Peking University Institute of Information Technology to develop a smart phone application which can be personalized medication reminder, record medication compliance, home blood pressure and blood glucose test results, also can provide doctor-patient communication platform and symptoms alarm. The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform. Whole blood-impedance based platelet aggregation(WBA) method and VerifyNow detected by aspirin or clopidogrel responsiveness will provide individualized anti-platelet drug selection. Control group will be selected from the National Stroke data registration database platform and open platform for stroke prevention. Follow-up period is 2 years. Endpoint event is defined as stroke death or relapse. Primary measure outcomes are change of the stroke recurrence rate and mortality after secondary prevention.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • refusion in research

研究组 & 干预措施

Mobile terminal

Experimental

Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.

干预措施: Mobile terminal (Procedure)

traditional management

Active Comparator

Stroke received traditional management for secondary prevention administration

干预措施: traditional management (Procedure)

website platform management

Active Comparator

Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.

干预措施: website platform management (Procedure)

结局指标

主要结局

change of the stroke recurrence rate

时间窗: 2 years stroke recurrence rate

After secondary prevention

次要结局

  • change of the stroke mortality(2 years stroke mortality)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fan Dongsheng

Chairman of Neurology Department

Peking University Third Hospital

研究点 (1)

Loading locations...

相似试验